INCY Valuation

Incyte Corp

Add to Watchlist

Advanced Chart

102.060

+0.3(0.295%)1D

INCY Relative Valuation

INCY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INCY is overvalued; if below, it's undervalued.

Historical Valuation

Incyte Corp (INCY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 13.45 is considered Undervalued compared with the five-year average of 19.38. The fair price of Incyte Corp (INCY) is between 131.14 to 224.27 according to relative valuation methord. Compared to the current price of 102.06 USD , Incyte Corp is Undervalued By 22.17%.

Relative Value

Fair Zone

131.14-224.27

Current Price：102.06

22.17%

Undervalued

13.45

Trailing

Forward

9.47

EV/EBITDA

Incyte Corp. (INCY) has a current EV/EBITDA of 9.47. The 5-year average EV/EBITDA is 14.83. The thresholds are as follows: Strongly Undervalued below 2.42, Undervalued between 2.42 and 8.62, Fairly Valued between 21.03 and 8.62, Overvalued between 21.03 and 27.23, and Strongly Overvalued above 27.23. The current Forward EV/EBITDA of 9.47 falls within the Historic Trend Line -Fairly Valued range.

8.52

EV/EBIT

Incyte Corp. (INCY) has a current EV/EBIT of 8.52. The 5-year average EV/EBIT is 16.94. The thresholds are as follows: Strongly Undervalued below 1.57, Undervalued between 1.57 and 9.25, Fairly Valued between 24.62 and 9.25, Overvalued between 24.62 and 32.31, and Strongly Overvalued above 32.31. The current Forward EV/EBIT of 8.52 falls within the Undervalued range.

3.71

Incyte Corp. (INCY) has a current PS of 3.71. The 5-year average PS is 4.14. The thresholds are as follows: Strongly Undervalued below 1.77, Undervalued between 1.77 and 2.96, Fairly Valued between 5.32 and 2.96, Overvalued between 5.32 and 6.50, and Strongly Overvalued above 6.50. The current Forward PS of 3.71 falls within the Historic Trend Line -Fairly Valued range.

12.85

P/OCF

Incyte Corp. (INCY) has a current P/OCF of 12.85. The 5-year average P/OCF is 18.46. The thresholds are as follows: Strongly Undervalued below 6.06, Undervalued between 6.06 and 12.26, Fairly Valued between 24.67 and 12.26, Overvalued between 24.67 and 30.87, and Strongly Overvalued above 30.87. The current Forward P/OCF of 12.85 falls within the Historic Trend Line -Fairly Valued range.

12.92

P/FCF

Incyte Corp. (INCY) has a current P/FCF of 12.92. The 5-year average P/FCF is 24.42. The thresholds are as follows: Strongly Undervalued below -1.12, Undervalued between -1.12 and 11.65, Fairly Valued between 37.18 and 11.65, Overvalued between 37.18 and 49.95, and Strongly Overvalued above 49.95. The current Forward P/FCF of 12.92 falls within the Historic Trend Line -Fairly Valued range.

Incyte Corp (INCY) has a current Price-to-Book (P/B) ratio of 4.30. Compared to its 3-year average P/B ratio of 3.46 , the current P/B ratio is approximately 24.40% higher. Relative to its 5-year average P/B ratio of 4.20, the current P/B ratio is about 2.45% higher. Incyte Corp (INCY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 3.51%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 3.16% , the current FCF yield is about -100.00% lower.

4.30

P/B

Median3y

3.46

Median5y

4.20

5.99

FCF Yield

Median3y

3.51

Median5y

3.16

Competitors Valuation Multiple

The average P/S ratio for INCY's competitors is 9.79, providing a benchmark for relative valuation. Incyte Corp Corp (INCY) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 20.05%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Ascentage Pharma Group International

Performance Decomposition

Market capitalization of INCY increased by 36.83% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 9.36 to 31.05.

The secondary factor is the Revenue Growth, contributed 20.05%to the performance.

Overall, the performance of INCY in the past 1 year is driven by Margin Expansion. Which is more sustainable.

20.05%

1.14B → 1.37B

Revenue Growth

231.73%

9.36 → 31.05

Margin Expansion

-214.95%

-15.04 → 17.29

P/E Change

36.83%